First Patient dosed in Ph 1 Trial of CBX-663 for Treatment of Multiple Hematologic and Solid Malignancies September 16, 2026
Simcere Zaiming Enters Exclusive License Agreement with Roche for SIM0660 Global Development September 9, 2026
Supplemental NDA to FDA submitted for Accelerated Approval for XPOVIO (selinexor) in combination with ruxolitinib for patients with myelofibrosis September 2, 2026
FDA clears IND application for ORM-1153 for Ph 1 study in patients with R/R AML and other hematologic malignancies August 25, 2026
Ipsen completes acquisition of Kartos Therapeutics, strengthening late-stage Oncology pipeline August 25, 2026
US FDA Type C Statistical Methods Meeting Granted to Review 2.5-Year OS Data for OST-HER2 in Metastatic Osteosarcoma August 20, 2026
Planned August sNDA Submission for Selinexor + Ruxolitinib in Myelofibrosis under the Accelerated Approval Pathway Remains on Track August 20, 2026
Supplemental NDA submission for Selinexor Plus Ruxolitinib in Myelofibrosis Planned Under Accelerated Approval Pathway August 5, 2026
BeOne Medicines Expands U.S. Manufacturing with More Than $1 Billion Investment to Advance Cancer Medicines July 28, 2026
FDA Accepts NDA for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma; PDUFA: May 2027 July 15, 2026
Allotera Therapeutics (Formerly Wugen) Closes $35 Million Financing to Advance Off-the-Shelf CAR-T Therapies for T-Cell Cancers July 15, 2026
Clinical Update Announced from CERTAIN-T Ph 1 CER-1236 Trial, Including Patient Undergoing Allogeneic Stem Cell Transplant Following Treatment June 17, 2026
Roche and Nurix Therapeutics to co-develop and co-commercialise bexobrutideg across malignant haematology, immunology and neurology June 10, 2026
Liminatus Pharma Announces Proposed Merger with InnocsAI to Expand Oncology Cell Therapy Pipeline May 26, 2026
US FDA RMAT Designation Granted to Orca-Q® for the Treatment of High-Risk Hematologic Malignancies May 6, 2026
Lilly to acquire Ajax Therapeutics to advance outcomes for patients with myelofibrosis and polycythemia vera April 28, 2026
IASO Bio Establishes International Partnership with Instituto Butantan to Develop Innovative Therapy for Hematological Cancer April 21, 2026
Crossbow Therapeutics raised $77 million in Series B financing to support completion of CROSSCHECK‑001 Ph 1 clinical trial of CBX‑250, and accelerate development of additional T‑Bolt™ immunotherapies March 24, 2026
Zemcelpro® (dorocubicel) positive results in high- and very high-risk blood cancers to be reported March 17, 2026
Servier and Day One Biopharmaceuticals announce acquisition to expand Servier’s rare oncology portfolio March 10, 2026
